<code id='D604613323'></code><style id='D604613323'></style>
    • <acronym id='D604613323'></acronym>
      <center id='D604613323'><center id='D604613323'><tfoot id='D604613323'></tfoot></center><abbr id='D604613323'><dir id='D604613323'><tfoot id='D604613323'></tfoot><noframes id='D604613323'>

    • <optgroup id='D604613323'><strike id='D604613323'><sup id='D604613323'></sup></strike><code id='D604613323'></code></optgroup>
        1. <b id='D604613323'><label id='D604613323'><select id='D604613323'><dt id='D604613323'><span id='D604613323'></span></dt></select></label></b><u id='D604613323'></u>
          <i id='D604613323'><strike id='D604613323'><tt id='D604613323'><pre id='D604613323'></pre></tt></strike></i>

          knowledge

          knowledge

          author:hotspot    Page View:39
          People taking notes while sitting around a meeting table
          Adobe

          It makes sense in theory for hospitals and startups to strike deals. Not only would doctors get first dibs on new health care technologies, their organizations would see windfalls if those startups hit it big.

          In practice, it often doesn’t work out that way. Doctors and other clinicians have their own way of doing things, and they typically don’t take kindly to an administrator telling them to learn a new product, especially if the goal is financial gain.

          advertisement

          Several health system-venture capital arrangements have fallen victim to this dynamic — but VC firm General Catalyst said this week it will buy nonprofit Summa Health, anyway.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi
          Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more

          Roche’s Alnylam deal shows drug firms interested in heart drugs

          AdobeRoche’sannouncementMondaythatitwouldpay$310millionforrightstoahypertensiontreatment,zilebesiran